flutamide and quinazolines

flutamide has been researched along with quinazolines in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chan, FL; Chang, C; Huang, J; Lee, YF; Lin, WJ; Messing, EM; Wilding, G	1
Ardito, R; Bianchino, G; Boninsegna, A; Camerini, A; Cittadini, A; Faraglia, B; Sgambato, A; Spada, D; Valentini, V	1

Other Studies

2 other study(ies) available for flutamide and quinazolines

Article	Year
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer research, 2002, Nov-01, Volume: 62, Issue:21 Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins	2002
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. Journal of cellular physiology, 2004, Volume: 201, Issue:1 Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Flutamide; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Tumor Suppressor Proteins	2004

Article

Year

Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.

Cancer research, 2002, Nov-01, Volume: 62, Issue:21

Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins

2002

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

Journal of cellular physiology, 2004, Volume: 201, Issue:1

Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Flutamide; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Tumor Suppressor Proteins

2004